A Multi-Center, Double-Blind, Placebo-Controlled Phase II Study of Pioglitazone in Early Parkinson's Disease.
Phase of Trial: Phase II
Latest Information Update: 19 Oct 2015
At a glance
- Drugs Pioglitazone (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Acronyms FS-ZONE
- 07 Oct 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 04 Sep 2012 Planned end date changed from 1 Apr 2013 to 1 Jul 2014 as reported by ClinicalTrials.gov.
- 17 May 2011 New source identified and integrated (Oregon Health and Science University).